Comparison

GHK-Cu vs
NAD+

One is a copper complex of a short peptide. The other is a coenzyme. Their evidence and regulatory records need to be read on their own terms.

Short answerCompound research · 6 min read · Updated 21 Nov 2026

GHK-Cu and NAD+ are different kinds of molecules: GHK-Cu is a copper complex of the three-amino-acid peptide GHK, while NAD+ is a coenzyme, not a peptide. GHK-Cu’s human record is early: small studies on skin, some of them randomised. Pooled trials of NAD+ and nicotinamide riboside found no main-outcome difference (2026).

Key takeaways

  • GHK-Cu is the copper complex of glycyl-L-histidyl-L-lysine; NAD+ is a coenzyme, not a peptide.
  • GHK-Cu’s human studies are small and on skin; for NAD+, a 2026 analysis pooling four trials of NAD+ and nicotinamide riboside found no significant difference from placebo in its main outcomes.
  • FDA’s 503A list (updated 14 May 2026) places GHK-Cu, for certain routes of administration only, and NAD in Category 1, “Bulk Drug Substances Under Evaluation”.
  • The TGA says NAD, NAD+ and NADH “are currently not permitted ingredients” in listed medicines; the Poisons Standard October 2026 names neither GHK-Cu nor NAD+.
  • Neither is named on WADA’s 2026 or 2027 List. WADA says a peptide not specifically named “may still be prohibited”; for NAD+, not a peptide, anti-doping organisations decide how the List’s classes apply.

01GHK-Cu vs NAD+ in one table

Identity, evidence and status records checked on 21 November 2026. A regulatory entry is not a verdict on every product bearing a molecule’s name.

QuestionGHK-CuNAD+
What it isA copper complex of the tripeptide glycyl-L-histidyl-L-lysine.Nicotinamide adenine dinucleotide, a coenzyme; it is not a peptide.
Evidence tier and human dataEarly human, as graded on its guide: small studies on skin, some randomised, among them one of a skin-care regimen with 13 completers (2006). Material sold online is not the formulation tested. Animal (T3) and cell (T4) work is on its guide.Human trials are small (T1), as graded on its guide. A 2026 analysis that pooled four trials of NAD+ and nicotinamide riboside found no significant difference from placebo in its main outcomes, and a rise in a kidney marker with NAD+.
United StatesFDA’s 503A list (updated 14 May 2026) places GHK-Cu, for certain routes of administration only, in Category 1, “Bulk Drug Substances Under Evaluation”; it is not in HHS’s October 2026 draft policy.FDA’s 503A list places NAD in the same category. Drugs@FDA lists no product containing nadide or nicotinamide adenine dinucleotide (openFDA, 21 Nov 2026).
AustraliaThe TGA says “many products promoted online are unapproved therapeutic goods and may be unlawful to import, supply or advertise. Using unapproved peptide products can pose serious health risks.” GHK-Cu has no entry by name in the Poisons Standard October 2026, which has group entries for copper compounds; we draw no scheduling conclusion of our own.The TGA says NAD, NAD+ and NADH “are currently not permitted ingredients” in listed medicines (safety alert, last updated 3 Feb 2026). The Poisons Standard October 2026 does not name it; we draw no scheduling conclusion of our own.
United KingdomThe emc medicines database returned no results for GHK, copper tripeptide or prezatide (21 Nov 2026); it is not the full UK register.The emc database returned no results for nadide or nicotinamide adenine dinucleotide (21 Nov 2026); it is not the full UK register.
SportNot named on the 2026 or 2027 List. WADA says a peptide not specifically named “may still be prohibited”.Not named on the 2026 or 2027 List. The List’s classes include substances it does not name, and anti-doping organisations decide how they apply.

For the next evidence question, read the GHK-Cu research guide. To learn what a lot-specific lab report can and cannot establish, see how to read a COA.

02How do their identities differ?

GHK-Cu names a complex: copper bound to GHK, a chain of three amino acids. The “Cu” identifies the copper component. That molecular description is not proof of what a particular vial contains.

NAD+ stands for nicotinamide adenine dinucleotide. It is a coenzyme, not a peptide. Calling both substances “peptides” would blur a basic difference in molecular identity.

Peptide

GHK

Three amino acids form the peptide part of the name.

Complex

GHK-Cu

The name describes GHK associated with copper; a label alone does not verify vial contents.

Coenzyme

NAD+

A different molecular class. It is not a chain of amino acids.

03What can the evidence comparison tell you?

Evidence tiers describe particular studies, not a universal score for a molecule. GHK-Cu has small human studies on skin as well as cell and animal research. Human studies vary in design and context, so a short label such as “human evidence” cannot stand in for a study-by-study account.

NAD+ has its own small trials, graded T1 on its guide; they measured different things in different people from the GHK-Cu skin studies. Putting both on one scale would imply a comparison that no study has made.

If you searched “nad vs ghk cu,” the clearest answer is that their identities differ, while the evidence needs separate assessment. A study of one does not establish findings about the other. Nor does a molecule’s name confirm the identity or contents of material sold under that name.

1
Start with the exact molecule

Check whether a paper studied GHK-Cu, NAD+, a related molecule or a different formulation.

2
Read the study design

Separate cell, animal and human studies. Then check what each study measured and what it did not.

3
Keep the limits attached

A finding in one study does not establish a general effect or a ranking between these molecules.

04What do the regulatory records say?

The table gives what each document says on the date shown. None is a legal conclusion of ours.

United States. FDA’s 503A list (updated 14 May 2026) places GHK-Cu, for certain routes of administration only, and NAD in Category 1, which FDA labels “Bulk Drug Substances Under Evaluation”. FDA has said it intends to consult its Pharmacy Compounding Advisory Committee on GHK-Cu before the end of February 2027.

Australia. The TGA says “many products promoted online are unapproved therapeutic goods and may be unlawful to import, supply or advertise. Using unapproved peptide products can pose serious health risks.” Neither GHK-Cu nor NAD+ is named in the Poisons Standard October 2026, which has group entries for copper compounds; separately, the TGA says NAD, NAD+ and NADH “are currently not permitted ingredients” in listed medicines. We draw no scheduling conclusion of our own.

United Kingdom. The emc medicines database returned no results for GHK, copper tripeptide, prezatide, nadide or nicotinamide adenine dinucleotide (21 November 2026). It is not the full UK register.

Sport. Neither is named on WADA’s 2026 or 2027 List. WADA says a peptide not specifically named “may still be prohibited”, and that a substance not found on the List should be checked with your anti-doping organisation.

05What we don’t know

  • Any study that compared GHK-Cu with NAD+: we found none (PubMed, 21 November 2026).
  • Whether the small GHK-Cu skin studies or the small NAD+ trials say anything beyond the people and measures they studied.
  • How anti-doping organisations would apply the List’s classes to either molecule, since the List names neither.
  • What a particular vial contains: a name or a regulatory entry cannot establish that.

This is a plain-English summary of selected public records, checked on 21 November 2026. It is not legal or medical advice.

RefSources

  1. U.S. Food and Drug Administration. Bulk drug substances nominated for use in compounding under section 503A (categories 1 to 3). List updated 14 May 2026; read 21 Nov 2026. www.fda.gov/media/94155/download
  2. U.S. Department of Health and Human Services. Enforcement discretion policy regarding 503A compounding using certain peptide bulk drug substances (draft), Appendix B. Read on the Internet Archive capture of 15 Nov 2026, the newest readable one (hhs.gov returned 403 to our tools). web.archive.org/web/20261115103435/https://www.hhs.gov/sites…
  3. U.S. Food and Drug Administration. Drugs@FDA data through openFDA: searches for nadide and nicotinamide adenine dinucleotide as active ingredients, no match (control, semaglutide: found). Database queries, 21 Nov 2026. api.fda.gov/drug/drugsfda.json?search=products.active_ingred…
  4. Therapeutic Goods Administration. NAD, NAD+, NADH or NMN medicines sold in Australia. Safety alert, published 7 Apr 2025, last updated 3 Feb 2026; read on the Internet Archive capture of 18 Apr 2026, the newest available (tga.gov.au did not respond to our tools). web.archive.org/web/20260418171031/https://www.tga.gov.au/sa…
  5. Therapeutic Goods Administration. Peptide products. Topic page, last updated 23 Sep 2026; read on the Internet Archive capture of 5 Nov 2026, the newest (tga.gov.au did not respond to our tools). web.archive.org/web/20261105200754/https://www.tga.gov.au/re…
  6. Therapeutic Goods (Poisons Standard—October 2026) Instrument 2026 (F2026L01327). Federal Register of Legislation, commenced 1 Oct 2026; text searched 21 Nov 2026. www.legislation.gov.au/F2026L01327/latest/text
  7. Electronic medicines compendium (emc). Searches for GHK, copper tripeptide and prezatide: “No search results” (control search, somatropin: 21 results). Database searches, 21 Nov 2026. www.medicines.org.uk/emc/search?q=GHK
  8. Electronic medicines compendium (emc). Searches for nadide and nicotinamide adenine dinucleotide: “No search results” (control search, somatropin: 21 results). Database searches, 21 Nov 2026. www.medicines.org.uk/emc/search?q=nadide
  9. PubChem. Nadide (nicotinamide adenine dinucleotide), CID 5892. Compound record, read 21 Nov 2026. pubchem.ncbi.nlm.nih.gov/compound/5892
  10. Hamzah KA, Kurmasha YH, Elshabrawi MN, et al. [Systematic review and meta-analysis of four randomised placebo-controlled trials of NAD+ or nicotinamide riboside.] Eur J Clin Pharmacol, 2026;82(12):295. PMID 43040090 (abstract read 21 Nov 2026). pubmed.ncbi.nlm.nih.gov/43040090/
  11. Miller et al. [Randomized study of a skin-care regimen after resurfacing]. Arch Facial Plast Surg, 2006; PMID 16847171. journals.sagepub.com/doi/10.1001/archfaci.8.4.252
  12. Mulder GD et al. [Randomized, evaluator-blinded study of a copper-peptide gel in a clinical wound-care setting]. Wound Repair Regen, 1994; PMID 17147644. pubmed.ncbi.nlm.nih.gov/17147644/
  13. World Anti-Doping Agency. Prohibited List 2026. International Standard, in force 1 January 2026; read 21 Nov 2026. www.wada-ama.org/sites/default/files/2025-09/2026list_en_fin…
  14. World Anti-Doping Agency. Prohibited List 2027. International Standard, in force 1 January 2027; read 21 Nov 2026. www.wada-ama.org/sites/default/files/2026-11/2027list_en_fin…
  15. World Anti-Doping Agency. 2027 Prohibited List: summary of major modifications and explanatory notes (S0, peptides). Explanatory note; read 21 Nov 2026. www.wada-ama.org/sites/default/files/2026-09/2027_list_expla…
  16. World Anti-Doping Agency. The Prohibited List (“The List is updated at least annually”; “If you cannot find a Substance or Method listed, please verify its status with your Anti-Doping Organization”). Web page, read 21 Nov 2026. www.wada-ama.org/en/prohibited-list

Plain-English summary of public sources, not legal or medical advice. Last checked 21 Nov 2026.

Questions

Is NAD+ a peptide?

No. NAD+ is nicotinamide adenine dinucleotide, a coenzyme. GHK-Cu is a copper complex of a three-amino-acid peptide.

What evidence tier does each have?

GHK-Cu: early human, from small studies on skin, as graded on its guide. NAD+: small trials (T1), as graded on its guide. The two grades describe different studies and are not a ranking.

What does FDA’s Category 1 mean?

FDA labels Category 1 “Bulk Drug Substances Under Evaluation”: substances nominated for its 503A compounding list that it is still evaluating. GHK-Cu, for certain routes only, and NAD are both in it (list updated 14 May 2026).

What does the TGA say about NAD+ in Australia?

The TGA says NAD, NAD+ and NADH “are currently not permitted ingredients” in listed medicines (safety alert, last updated 3 February 2026). The Poisons Standard October 2026 does not name NAD+; we draw no scheduling conclusion of our own.

Does WADA name either molecule?

No. Neither is named on the 2026 or 2027 List. WADA says a peptide not specifically named “may still be prohibited”; for any substance not listed, it says “please verify its status with your Anti-Doping Organization”.

Evidence before hype.

One email a week: new research explained and regulatory changes. No prices, no hype.

Get the 6:00 brief

Free. Unsubscribe any time.

Written by 6AM Research. Drafted from primary sources; every claim links to its source, and the page is dated. Editorial policy · How we check every page